This study is looking at differences in metabolism and functional imaging between pulmonary hypertension subjects with normal right ventricular function and persistent right ventricular dysfunction.
We will measure right ventricular metabolic and structural changes using serial 11C-acetate and 18F-FDG PET/CT and cardiac MRI as response to treatment with ranolazine. Subjects undergo imaging procedures at week 0 and week 26 (optional for normal function patients). This is a companion imaging trial for patients who are eligible for the treatment trial entitled "A randomized, double-blind, placebo controlled, multi-center study to assess the effect of ranolazine on outcomes in subjects with pulmonary hypertension and right ventricular dysfunction accompanied by a comparative study of cellular metabolism in subjects with pulmonary hypertension with and without right ventricular dysfunction". Subjects must enroll in companion treatment protocol to qualify for the imaging protocol. The cardiac MRI portion of the study continued, but the PET portion of the study was discontinued due to funding. The treatment protocol is registered under: NCT01839110. Due to funding issues, the completed study was registered under NCT02829034.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
21
For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Changes in RV Function
RV function as measured by cardiac MRI
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.